Synthesis, Characterization, and in vivo Evaluation of a Novel Potent Autotaxin-Inhibitor.
Hunziker D, Reinehr S, Palmhof M, Wagner N, Biniasch T, Stute G, Mattei P, Schmitz P, DiGiorgio P, Hert J, Rudolph MG, Benz J, Stihle M, Gsell B, Müller S, Gasser R, Schonhoven N, Ullmer C, Joachim SC.
Hunziker D, et al.
Front Pharmacol. 2022 Jan 18;12:699535. doi: 10.3389/fphar.2021.699535. eCollection 2021.
Front Pharmacol. 2022.
PMID: 35126098
Free PMC article.
In order to inhibit or modulate this pathway, we developed a new series of ATX-inhibitors containing novel bicyclic and spirocyclic structural motifs. A potent lead compound (IC(50) against ATX: 6 nM) with good in vivo PK, favorable in vitro property, and safety profile wa …
In order to inhibit or modulate this pathway, we developed a new series of ATX-inhibitors containing novel bicyclic and spirocyclic s …